CellVoyant’s platform combines AI with live cell imaging
Category: News
If successful, the new test could see routine screening introduced in the NHS
The diagnostic system can deliver particles to the lungs via aerosol or a nebuliser
In 2022, around 8% of patients survived 30 days after a cardiac arrest
The £30m ADVANCE study is the most extensive study into liver disease worldwide
The partnership will advance VTP-500 from early development to phase 2 clinical trials
Both aim to advance the use of AI-powered cell analysis for cancer, stem cell and cell therapies
The fertilised eggs could cultivate tumours for imaging within seven days
The nine-week DTxl CBT helps to address psychological symptom burdens in PF patients
